Rare Benign Fat-Containing Bone Tumor | Classic Central Calcification | Calcaneus Most Common Site
- Calcaneus is the most common site - accounts for 60% of all intraosseous lipomas
- Central calcification on X-ray is pathognomonic - radiolucent lesion with dense central nidus
- MRI shows fat signal on all sequences - diagnostic feature distinguishing from other lucent lesions
- Completely benign - no malignant potential and excellent prognosis with simple curettage
- Milgram staging based on degree of fat necrosis and calcification, not biological behavior
- “Examiners love the central calcification pattern - it's pathognomonic for intraosseous lipoma
- “Fat signal on MRI (high T1, low T2 with fat suppression) clinches the diagnosis
- “Distinguish from bone infarct - infarcts have serpentine peripheral calcification, lipomas have central calcification
- “Simple curettage is curative - no wide margins needed as this is completely benign
Central calcification on X-ray - radiolucent lesion with dense central nidus of calcification. This is the classic radiographic appearance distinguishing lipoma from other lucent lesions.
High T1 signal that suppresses with fat saturation. This confirms fat content and distinguishes intraosseous lipoma from other radiolucent lesions like SBC or UBC.
60% occur in calcaneus followed by proximal femur (20%). Rare in other sites. Think intraosseous lipoma for any lucent calcaneal lesion with central calcification.
Completely benign with no malignant potential. Simple curettage is curative. Recurrence is rare (under 5%) and indicates incomplete excision.
- Imaging Features
- Radiolucent with central calcification, fat on MRI
- Management
- Observation - no treatment needed
- Key Pearl
- Benign, no growth potential
- Imaging Features
- Small lesion, intact cortex
- Management
- Conservative - analgesia, activity modification
- Key Pearl
- Most never become symptomatic
- Imaging Features
- Cortical thinning, pathological fracture risk
- Management
- Curettage with bone graft or substitute
- Key Pearl
- Simple curettage is curative
Overview and Epidemiology
Intraosseous lipoma is a rare benign tumor composed of mature adipose tissue within the medullary cavity of bone. Despite being uncommon (under 0.1% of all bone tumors), it has a characteristic imaging appearance that makes it an important diagnosis to recognize. The pathognomonic central calcification on radiographs and fat signal on MRI allow confident diagnosis without biopsy in most cases.
- Age: 40-60 years (middle-aged adults)
- Gender: Equal distribution (no gender predilection)
- Rare in children: Under 5% of cases
- Usually solitary: Multiple lipomas exceptionally rare
- Calcaneus: 60% (most common site by far)
- Proximal femur: 20% (intertrochanteric region)
- Tibia: 5% (proximal metaphysis)
- Fibula, ribs, skull: Rare (under 5% each)
- Never in spine: Unlike soft tissue lipomas
Pathophysiology and Mechanisms
Origin and Histogenesis
The exact origin of intraosseous lipoma is unknown. Several theories have been proposed:
Most accepted theory: Metaplastic transformation of bone marrow mesenchymal cells to adipocytes in response to:
- Trauma or microtrauma
- Ischemia or infarction
- Unknown stimulus
Alternative theory: Congenital nidus of ectopic fat cells that slowly expands over time.
Less favored as most cases present in adulthood, not childhood.
Milgram Histological Classification
The Milgram staging system classifies intraosseous lipomas based on histological features reflecting the natural evolution from viable fat to necrosis and calcification.
- Histology
- Viable adipose tissue only
- Radiographic Appearance
- Radiolucent, no calcification
- Clinical Significance
- Early lesion, purely fatty
- Histology
- Fat necrosis with focal calcification
- Radiographic Appearance
- Radiolucent with central calcification
- Clinical Significance
- Classic appearance - most common
- Histology
- Extensive calcification and cyst formation
- Radiographic Appearance
- Heavily calcified, may mimic bone infarct
- Clinical Significance
- Advanced involution, difficult to diagnose
Important concept: The Milgram staging system reflects the natural involution of the lipoma from viable fat to necrotic calcified tissue. It does NOT indicate biological behavior or malignant potential. All stages are equally benign.
Why Central Calcification?
The characteristic central calcification occurs due to:
- Fat necrosis in the center of the lesion (ischemia or outgrowth of blood supply)
- Dystrophic calcification of necrotic fat cells
- Progressive calcification from center outward as lesion involutes
This contrasts with bone infarct, which shows peripheral serpentine calcification delineating the infarct margin.
Pathology
Gross Pathology
Macroscopic appearance: Yellow, greasy, soft tissue indistinguishable from normal adipose tissue. May have areas of white chalky calcification (fat necrosis).
Size: Typically 2-5 cm diameter, rarely larger.
Histology
- Mature adipocytes: Large cells with single lipid vacuole displacing nucleus to periphery
- Minimal atypia: Cells look like normal fat
- Fat necrosis (Stage 2-3): Ghost cells, loss of cell membranes
- Dystrophic calcification: Calcium deposits in necrotic fat
- Reactive bone: Woven bone at periphery in some cases
Distinguish from:
- Normal marrow fat: Lipoma is expansile mass, not just fatty marrow
- Liposarcoma: Lipoblasts (cells with scalloped hyperchromatic nuclei), not present in benign lipoma
- Bone infarct: Geographic necrosis of bone and marrow, calcification at periphery
Histologically, intraosseous lipoma is indistinguishable from soft tissue lipoma - both show mature adipose tissue. The key is the intramedullary location within bone and the central calcification pattern that is unique to intraosseous lipoma.
Classification and Staging
Milgram Histological Classification (1988)
Gold standard for intraosseous lipoma classification based on histological appearance.
Stages and Natural History
Histology: Mature adipose tissue with intact cell membranes, normal nuclei, and viable fat cells.
Radiology: Purely radiolucent lesion, no calcification visible.
Prevalence: Uncommon (10-15% of cases) - most lesions progress to Stage 2 before clinical detection.
Histology: Viable fat at periphery, central fat necrosis with dystrophic calcification.
Radiology: Radiolucent lesion with central calcification - pathognomonic appearance.
Prevalence: Most common (60-70% of cases) - this is the classic imaging appearance.
Histology: Extensive calcification, minimal residual fat, cyst formation, reactive bone.
Radiology: Heavily calcified lesion, may mimic bone infarct or enchondroma.
Prevalence: Less common (20-25%) - advanced involution, difficult diagnosis.
Stage 2 lesions represent the classic intraosseous lipoma with pathognomonic central calcification on X-ray. This is the most commonly encountered stage and the easiest to diagnose radiographically. Stage 1 (no calcification) and Stage 3 (extensive calcification) can be more challenging to recognize.
STAGE 1-2-3Milgram Histological Staging
Hook:Stages progress from Simple fat (Stage 1) to Transitional necrosis (Stage 2) to Advanced calcification (Stage 3). All are benign!
Clinical Presentation
- Asymptomatic: 50-70% (incidental finding on imaging)
- Pain: 30-50% - dull, aching, activity-related
- No systemic symptoms: Never presents with fever, weight loss, malaise
- Pathological fracture: Rare (under 5%) but possible if large lesion with cortical thinning
- Chronic pain: Months to years if symptomatic
- Stable size: No progressive enlargement (unlike malignant lesions)
- Incidental discovery: Often found during imaging for other reasons
- Slow involution: May calcify and become more apparent over years
Physical Examination
- No visible swelling: Intramedullary location prevents external mass
- No skin changes: No erythema, warmth, or overlying soft tissue abnormality
- Tenderness: May have mild focal tenderness over lesion site
- Normal neurovascular exam: No nerve or vessel involvement
- Full range of motion: Adjacent joints unaffected
- Normal gait: If calcaneal, may have antalgic gait if painful
- No deformity: Unless pathological fracture occurred
- Weight-bearing: Tolerated unless fracture or severe pain
These features suggest alternative diagnosis:
- Rapid growth or increasing size (consider malignancy)
- Soft tissue mass extending beyond bone (not characteristic of intraosseous lipoma)
- Systemic symptoms (fever, weight loss - consider infection or malignancy)
- Pathological fracture through aggressive-appearing lesion (reassess diagnosis)
Clinical Scenarios
- Typical Patient
- 50-year-old, ankle X-ray for sprain
- Imaging Indication
- X-ray shows lucent calcaneal lesion with central calcification
- Management
- Reassure patient, no treatment needed
- Typical Patient
- 45-year-old with 6 months heel pain, no trauma
- Imaging Indication
- MRI confirms fat signal lesion in calcaneus
- Management
- Trial conservative management, consider curettage if persistent
- Typical Patient
- 60-year-old with hip pain, large lesion with cortical thinning
- Imaging Indication
- MRI shows fat signal, concern for fracture risk
- Management
- Consider prophylactic curettage with bone graft
Imaging and Diagnosis
Plain Radiographs
Radiographic Features
Well-defined radiolucent lesion with narrow zone of transition. Geographic Type IA or IB (Lodwick classification).
Located in metaphysis or diaphysis of long bones, or within calcaneus body.
Dense central nidus of calcification within the lucent lesion. This is the PATHOGNOMONIC feature.
Calcification is typically round or oval, centrally located, distinct from peripheral rim calcification of bone infarct.
Cortex is intact or mildly thinned but not destroyed. No periosteal reaction unless pathological fracture.
Sclerotic rim may be present at margin between lesion and normal bone.
No extension beyond bone cortex. Intraosseous lipomas are purely intramedullary.
Distinguish intraosseous lipoma from bone infarct:
- Intraosseous lipoma: Central round/oval calcification (fat necrosis)
- Bone infarct: Peripheral serpentine calcification (geographic map pattern outlining infarct)
This is a classic exam distinction!
MRI - Gold Standard for Diagnosis
Diagnostic feature: Signal identical to subcutaneous fat on all sequences.
- T1-weighted: High signal (bright)
- T2-weighted: Intermediate to high signal
- STIR/Fat saturation: Signal SUPPRESSES completely
- No enhancement: Fat does not enhance with gadolinium
- Central calcification: Low signal nidus on all sequences
- Well-defined margins: Smooth interface with normal marrow
- No soft tissue extension: Confined within bone cortex
- No edema: Surrounding bone marrow normal (unless fracture)
The key to MRI diagnosis is demonstrating that the high T1 signal SUPPRESSES with fat saturation sequences (STIR or fat-sat T2). This proves the lesion contains fat, distinguishing it from other T1 hyperintense lesions like hemorrhage or proteinaceous cyst fluid.
CT Scan
CT is rarely needed but may show:
- Fat density (-40 to -120 Hounsfield units)
- Central calcification well-delineated
- Cortical integrity assessment
CT is useful for surgical planning if curettage planned, to assess cortical thinning and structural integrity.
Differential Diagnosis
- Key Distinguishing Feature
- Peripheral serpentine calcification
- Imaging Clue
- Geographic map pattern at periphery, NOT central
- Key Distinguishing Feature
- No central calcification, younger age
- Imaging Clue
- Fallen fragment sign, fluid signal on MRI
- Key Distinguishing Feature
- Expansile, fluid-fluid levels
- Imaging Clue
- Blow-out appearance, hemorrhagic fluid on MRI
- Key Distinguishing Feature
- Chondroid matrix calcification
- Imaging Clue
- Rings and arcs calcification, no fat signal
- Key Distinguishing Feature
- Ground-glass matrix, no fat signal
- Imaging Clue
- Expansile, no central calcification pattern
When to Biopsy
Biopsy is RARELY needed if imaging is classic (central calcification on X-ray, fat signal on MRI).
Classic imaging features allow confident diagnosis:
- Radiolucent lesion with central calcification
- Fat signal on MRI (high T1, suppresses with fat-sat)
- Typical location (calcaneus, proximal femur)
- Middle-aged patient
Atypical features raise diagnostic doubt:
- No fat signal on MRI (not a lipoma)
- Aggressive features (cortical destruction, soft tissue mass)
- Rapid growth or change in appearance
- Patient symptoms out of proportion to imaging
SAULICDifferential Diagnosis of Radiolucent Calcaneal Lesions
Hook:SAULIC covers the differential for lucent calcaneal lesions - Lipoma has central calcification and fat signal!
Management and Treatment
Observation Protocol
Indications for observation:
- Asymptomatic lesion discovered incidentally
- Classic imaging appearance (no diagnostic uncertainty)
- Small size with no risk of pathological fracture
- Patient preference to avoid surgery
Surveillance Schedule
Repeat X-ray at 6 months to confirm stability. Intraosseous lipomas do not grow.
If stable at 6 months, repeat X-ray at 1 year. If still stable, discharge from follow-up.
Educate patient that this is benign. Advise to return if new pain or symptoms develop.
Most intraosseous lipomas can be observed without treatment. Surgery is only indicated for symptomatic lesions or those with fracture risk. Asymptomatic incidental lesions require only reassurance and brief radiographic follow-up to confirm stability.
Complications
Surgical Complications
- Incidence
- Under 5%
- Prevention
- Complete curettage of all walls
- Management
- Re-curettage if symptomatic recurrence
- Incidence
- Rare (under 3%)
- Prevention
- Prophylactic fixation if large lesion with cortical thinning
- Management
- ORIF with bone graft
- Incidence
- 2-3%
- Prevention
- Standard sterile technique, prophylactic antibiotics
- Management
- Antibiotics, irrigation and debridement if deep infection
- Incidence
- Under 2%
- Prevention
- Careful approach avoiding neurovascular structures
- Management
- Observation for neuropraxia, exploration if transection suspected
Disease-Related Complications
- Pathological fracture: Rare (under 5%), occurs with large lesions and cortical thinning
- Chronic pain: Mechanism unclear, may be due to microfractures or pressure
- No systemic complications: Does not affect other organs
- No malignant transformation: Never reported in literature
- No recurrence after observation: Lesions do not grow
- No metastases: Does not spread
- No death: Never causes mortality
Liposclerosing Myxofibrous Tumour (LSMFT): the Key Intertrochanteric Mimic
The AFIP lipomatous-lesions reference cited in the Evidence Base names liposclerosing myxofibrous tumour as a key differential of the intertrochanteric femur, but the topic never develops it - which matters because it sits at the proximal femur, the second most common site of intraosseous lipoma, and behaves differently.
- A different, mixed lesion. LSMFT is a benign fibro-osseous lesion with a mixed histology - variable proportions of lipoma, fibrous tissue, myxoid change, fat necrosis, cyst formation, ischaemic ossification and ground-glass fibrous-dysplasia-like bone - rather than the pure mature fat of an intraosseous lipoma. It is characteristically located in the intertrochanteric region of the proximal femur (the great majority of cases).
- It does NOT look like a simple fatty lesion on MRI. Because of its mixed matrix, LSMFT usually does not follow fat signal uniformly - it shows heterogeneous T1/T2 signal, often with a fibrous-dysplasia-like or myxoid appearance and sometimes a sclerotic rim - so the reassuring "high T1 that fully suppresses with fat saturation" of a true intraosseous lipoma is typically absent. This is the discriminator.
- The critical difference - a real (if debated) risk of change. Unlike the true intraosseous lipoma, which has essentially zero malignant potential, LSMFT has a described, though contested and probably referral-biased, risk of malignant transformation (to malignant fibrous histiocytoma / osteosarcoma). For that reason a symptomatic, enlarging, or aggressive-appearing intertrochanteric LSMFT is treated with a lower threshold for biopsy and closer surveillance than a classic intraosseous lipoma.
- Why it is examined. It is the classic "intertrochanteric fibro-osseous lesion" that overlaps radiologically with intraosseous lipoma and fibrous dysplasia, and the point being tested is that a heterogeneous (non-purely-fatty) intertrochanteric lesion is NOT automatically a benign lipoma to be ignored.
Q: How does liposclerosing myxofibrous tumour differ from intraosseous lipoma, and why does it matter? A: LSMFT is a benign but MIXED fibro-osseous lesion (lipoma + fibrous + myxoid + fat necrosis + ossification + ground-glass bone) that is characteristically intertrochanteric, does NOT follow uniform fat signal on MRI (heterogeneous, fibrous-dysplasia-like), and - unlike the true intraosseous lipoma with its zero malignant potential - has a described (if contested) risk of malignant transformation. So a heterogeneous intertrochanteric lesion warrants a lower threshold for biopsy/surveillance, not the confident "benign fatty lesion, observe" line that applies to a classic intraosseous lipoma.
Parosteal (Juxtacortical) Lipoma: the Surface Bone Lipoma
The topic emphasises throughout that intraosseous lipoma is purely intramedullary with "no soft-tissue extension", and the same AFIP reference pairs it with its surface counterpart, parosteal lipoma ("fat in the marrow space or on the bone surface, respectively") - but that surface entity is never developed. It is the natural contrast and carries a distinctive clinical hazard.
- A fatty mass ON the bone surface. Parosteal (juxtacortical) lipoma is a benign lipoma arising on the outer surface of the cortex/periosteum, most often around the radius, femur, humerus and pelvis. Like the intraosseous type it is fat-signal on CT/MRI, but its location is juxtacortical, not intramedullary, and it frequently provokes a reactive bony excrescence / cortical hyperostosis or osteochondroma-like spur at its base - a useful radiographic clue.
- The clinical catch - nerve compression. Its surface location means it can compress an adjacent peripheral nerve. The classic and most examined example is a parosteal lipoma of the proximal radius compressing the posterior interosseous nerve (PIN), producing a PIN palsy / radial-tunnel-type presentation; similar compressive syndromes occur elsewhere. This is a real functional consequence that the intramedullary lipoma never causes.
- Diagnosis and treatment. MRI shows a fat-signal mass abutting the cortex with the reactive bony change, confirming the diagnosis without biopsy in typical cases. Because it is benign, marginal surgical excision is curative and is indicated when it is symptomatic or causing nerve compression (with neurolysis of the involved nerve); asymptomatic incidental lesions can be observed.
Q: What is a parosteal lipoma and how does it differ from intraosseous lipoma? A: A benign lipoma on the outer bone surface (juxtacortical/periosteal) - fat signal like the intramedullary type but located ON the cortex, often with a reactive bony excrescence/hyperostosis at its base. Its surface position lets it compress an adjacent nerve - classically a proximal-radius parosteal lipoma causing a posterior interosseous nerve (PIN) palsy. MRI (fat-signal surface mass + cortical reaction) is diagnostic; marginal excision (with neurolysis) is curative when symptomatic. This nerve-compression risk is the key contrast with the purely intramedullary intraosseous lipoma.
FAT CALCClassic Features of Intraosseous Lipoma
Hook:FAT CALC - the FAT shows CALCification! This describes the classic central calcification in a fat-containing lesion.
Postoperative Care
Post-Curettage Rehabilitation Protocol
Wound care and dressing changes. Weight-bearing status depends on site: calcaneus - partial weight-bearing in boot; proximal femur - protected weight-bearing with crutches.
Suture removal at 2 weeks. Progressive weight-bearing as tolerated. X-ray at 6 weeks to assess graft incorporation.
Full weight-bearing for most patients. Transition to normal footwear (calcaneus). Resume light activities.
Return to full activity including sports. Final X-ray to confirm healing and no recurrence. Discharge if stable.
- X-ray at 6 weeks and 3 months post-curettage
- Annual follow-up not required for confirmed benign lipoma
- Recurrence is rare (under 5%) - patient can be reassured
Outcomes and Prognosis
Surgical Outcomes
Curettage with or without bone graft is curative in over 95% of cases.
- Pain resolution: 95% of patients have complete pain relief
- No recurrence: Under 5% recurrence rate with complete curettage
- Bone healing: Grafted defects heal within 6-12 weeks
- Return to activity: Full activity by 3-6 months post-op
- Recurrence: Under 5% (incomplete curettage)
- Wound infection: Standard surgical site infection rates (2-3%)
- Pathological fracture: Rare if prophylactic measures taken
- Nerve injury: Site-specific (sural nerve in calcaneus)
Long-term Prognosis
Excellent. Intraosseous lipoma is completely benign with no malignant potential.
- No malignant transformation: Never reported
- No metastases: Does not metastasize
- No growth: Stable size, does not enlarge
- Natural involution: May calcify and involute (Stage 2 to Stage 3)
The prognosis is 100% excellent. This is a completely benign lesion with no malignant potential. Simple curettage is curative, and recurrence is rare. Patients can be confidently reassured that this is not cancer and will not become cancer.
Guidelines, Registries & Global Practice
Global Epidemiology
Intraosseous lipoma is reported worldwide with a consistent profile: peak presentation in middle age (mean ~43-48 years across pooled series), near-equal sex distribution, and a lower-limb predominance (~71% of cases), with the os calcis the single most common site. It is genuinely uncommon (classically quoted at under 0.1% of primary bone tumours) but is widely regarded as underdiagnosed because involuted (Milgram III) lesions are mistaken for cysts or bone infarcts. There is no dedicated tumour registry for this benign entity; epidemiology derives from radiology and orthopaedic-oncology case series rather than national arthroplasty/implant registries.
Guideline Framework (Side-by-Side)
- Relevant guidance
- Listed as a benign adipocytic bone tumour; diagnosis rests on identifying mature fat
- Practical implication
- Histology not required when imaging is unequivocal
- Relevant guidance
- Any indeterminate or aggressive-appearing bone lesion should be referred to a bone-tumour unit before biopsy
- Practical implication
- Refer only atypical cases; classic lipomas need no referral
- Relevant guidance
- "Diagnostic uncertainty or aggressive features" trigger sarcoma-unit referral
- Practical implication
- A confidently diagnosed fatty lesion is managed locally
- Relevant guidance
- Latent benign bone lesions (Enneking stage 1) may be observed
- Practical implication
- Curettage reserved for symptoms or fracture risk
No major society mandates routine biopsy or specialist referral for a radiologically classic intraosseous lipoma.
- MRI readily available to confirm fat signal and assign Milgram stage
- CT reserved for surgical planning (cortical integrity, fracture risk)
- Histological confirmation easily obtained when a lesion is curetted
- Plain radiograph (central calcification in a lucent calcaneal lesion) often sufficient for a confident working diagnosis
- Where MRI is unavailable, typical radiographic features plus stability on follow-up support observation
- Curettage with locally available graft or substitute is curative when surgery is needed
Across FRCS (Tr & Orth), FRACS, EBOT, ABOS and DNB/MS exams, be ready to describe the pathognomonic imaging features (central calcification on radiograph, fat signal on MRI that suppresses with fat saturation), the Milgram classification (Stages 1-3 reflecting involution, not malignancy), and to justify observation for asymptomatic lesions versus curettage and grafting for symptomatic or fracture-prone disease.
Controversies and Areas of Uncertainty
Campbell and colleagues questioned whether intraosseous lipoma is a genuine benign tumour of fat or the end-result of involution of pre-existing lesions and biomechanical stress (the constant os calcis location at the critical angle). The histogenesis remains unsettled.
Milgram reported four cases of presumed malignant transformation (liposarcoma / malignant fibrous histiocytoma) within bone lipomas. These are exceptionally rare and contested; for practical purposes the lesion is treated as having no meaningful malignant potential, but rapid bone destruction in a previously lucent lesion warrants reassessment.
There are no randomised data comparing observation with curettage. Practice is guided by symptoms and fracture risk: asymptomatic lesions are observed, symptomatic or structurally threatened lesions are curetted and grafted.
Phenolisation and extended (burr/argon) curettage are sometimes used by analogy with other bone lesions, but the Radl cohort found no added benefit from phenol, consistent with the benign biology. Aggressive adjuvants are not justified.
The single most important caveat is that a Milgram III lesion can mimic a bone infarct, and rare aggressive change has been described. If a lesion shows rapid growth, cortical destruction or a soft-tissue component, abandon the assumption of a benign lipoma and refer for bone-tumour assessment and biopsy.
MCQ Practice Points
Q: What is the most common site for intraosseous lipoma? A: Calcaneus accounts for 60% of all intraosseous lipomas, followed by proximal femur (20%). This is a high-yield fact.
Q: What is the pathognomonic radiographic finding of intraosseous lipoma? A: Central calcification within a radiolucent lesion. This dense central nidus of calcification distinguishes intraosseous lipoma from simple bone cyst and other lucent lesions.
Q: What MRI finding confirms the diagnosis of intraosseous lipoma? A: High T1 signal that suppresses with fat saturation sequences. This proves fat content and allows confident diagnosis without biopsy.
Q: What does the Milgram classification of intraosseous lipoma indicate? A: The Milgram classification (Stages 1-3) reflects the histological evolution from viable fat to necrosis and calcification. It does NOT indicate biological behavior or prognosis - all stages are equally benign.
Q: What are the indications for surgical treatment of intraosseous lipoma? A: Surgery indicated for: persistent pain unresponsive to conservative treatment, pathological fracture or imminent fracture risk (large lesion with cortical thinning), or diagnostic uncertainty. Asymptomatic lesions can be observed.
Q: What is the malignant potential of intraosseous lipoma? A: Zero. Intraosseous lipoma is completely benign with no reported cases of malignant transformation. Prognosis is excellent.
Exam Viva Scenarios
Practise clinical reasoning and management decisions out loud
“A 52-year-old woman presents after ankle sprain. X-ray shows a well-defined radiolucent lesion in the calcaneus with a central dense calcification. She has no heel pain. What is your diagnosis and management?”
“A 58-year-old man presents with 6 months of hip pain. Imaging shows a 5cm radiolucent lesion in the intertrochanteric region of the proximal femur with central calcification and significant cortical thinning. MRI confirms fat signal. How do you manage this?”
“A 45-year-old presents with a radiolucent lesion in the calcaneus. Your colleague suggests this is a simple bone cyst. The X-ray shows some central density. How do you differentiate between intraosseous lipoma and simple bone cyst? What additional imaging would you order?”
Key Facts
- Rare benign tumor - under 0.1% of all bone tumors
- Calcaneus most common site (60%), proximal femur (20%)
- Age 40-60 years, equal gender distribution
- Completely benign - no malignant potential
Pathognomonic Imaging
- Central calcification on X-ray - dense nidus within radiolucent lesion
- Fat signal on MRI - high T1, suppresses with fat saturation
- Distinguish from bone infarct - infarct has peripheral serpentine calcification
- MRI diagnostic - biopsy rarely needed if imaging classic
Milgram Classification
- Stage 1: Viable fat only - no calcification visible
- Stage 2: Fat necrosis with central calcification - most common (60-70%)
- Stage 3: Extensive calcification with cyst formation
- Staging reflects involution, NOT biological behavior - all benign
Clinical Presentation
- Asymptomatic (50-70%) - incidental finding
- Pain (30-50%) - dull, aching, activity-related
- Pathological fracture rare (under 5%) with large lesions
- No systemic symptoms
Management
- Asymptomatic: Observation with 6-month X-ray to confirm stability
- Symptomatic or fracture risk: Curettage with bone graft
- Prophylactic fixation if large lesion with cortical thinning
- Recurrence rare (under 5%) with complete curettage
Exam Pearls
- Central calcification = pathognomonic (vs peripheral in bone infarct)
- Fat on MRI confirms diagnosis - high T1, suppresses with fat-sat
- Calcaneus is #1 site - always think lipoma for lucent calcaneal lesion with central calcification
- Simple curettage curative - no wide margins needed (benign)
Evidence Base and Key Studies
Intraosseous Lipomas: A Clinicopathologic Study of 66 Cases (Original Milgram Classification)
- Landmark paper analysing 66 cases (61 histologically confirmed solitary lesions) that defined the still-used three-stage classification
- Stage I solid viable lipocytes; Stage II transitional fat necrosis with focal calcification plus viable fat; Stage III late involution with cyst formation, calcification and reactive bone
- The lesion undergoes spontaneous involution, so surgical excision may not be necessary in many cases
- Concluded intraosseous lipoma is not as rare as previously thought but is frequently underdiagnosed and confused with cysts and bone infarction
Intraosseous Lipoma: Report of 35 New Cases and a Review of the Literature
- 35 new cases plus meta-analysis of 110 further cases from the English-language literature (145 total)
- Mean age 43 years with near-equal sex distribution; 71% occur in the lower limb and 32% in the os calcis
- Central calcification far commoner in os calcis lesions (62%) than other sites (30%); marginal sclerosis 61% in os calcis vs 38% elsewhere
- Fat necrosis and cyst formation seen on MRI in 67% of cases - the radiological correlate of Milgram involution
Radiologic-Pathologic Correlation of Intraosseous Lipomas
- Correlated imaging appearances with histology across the three Milgram stages
- Stage 1 = uniform fat signal; Stage 2 = fat with central fat necrosis and calcification; Stage 3 = cystic degeneration, calcification and reactive bone
- MRI fat signal (matching subcutaneous fat, suppressing on fat-saturated sequences) is the key diagnostic feature
- Calcification and cystic change increase with stage, explaining why involuted lesions mimic bone infarct
Intraosseous Lipoma: Retrospective Analysis of 29 Patients (Surgical Outcomes)
- 29 patients (mean age 48 years) treated 1985-2002; Milgram stages I=10, II=14, III=3
- All treated by curettage; phenolisation added in 11 cases showed no added benefit
- No clinical or radiological recurrence at mean follow-up of 32 months (range 6-208)
- Asymptomatic lesions without impending fracture can be managed conservatively
Surgical Treatment of Confirmed Intraosseous Lipoma of the Calcaneus: A Case Series
- 14 patients with symptomatic calcaneal intraosseous lipoma treated by curettage (Milgram I=9, II=4, III=1)
- Mean VAS pain improved from 5.29 preoperatively to 1.14 at final follow-up (p less than 0.01)
- Mean Maryland foot score 97.7 and AOFAS ankle-hindfoot score 97.9 at final review
- No recurrence over a median follow-up of 84 months
From the Archives of the AFIP: Benign Musculoskeletal Lipomatous Lesions
- Authoritative AFIP pictorial review classifying benign lipomatous lesions of soft tissue, bone, joint and tendon sheath
- States intraosseous lipoma has a pathognomonic CT/MR appearance with fat in the marrow space
- Highlights liposclerosing myxofibrous tumour (intertrochanteric femur) as a key mimic and differential
- Reinforces that fat identification on cross-sectional imaging is diagnostic for the lipomatous family